| abstract |
The CB1 receptor is one of the most abundant neuroregulatory receptors in the brain and is expressed at high levels in the hippocampus, cortex, cerebellum, and basal ganglia. Compounds of formula (I), or pharmaceutically acceptable salts, solvates or esters thereof, are metabolic syndrome and obesity, neuroinflammatory disorders, cognitive and psychotic disorders, addiction (eg smoking cessation), gastrointestinal disorders and cardiovascular It is useful in treating diseases or conditions mediated by the CB1 receptor, such as conditions. The present invention provides novel substituted piperazine compounds as selective CB 1 receptor antagonists for the treatment of various conditions. |